Stephen W. Kaldor is Director at Furiex Pharmaceuticals, Inc. (FURX). They have made 1 open-market trade across 1 company since 2013, most recently 2014-07-02.
CIK 0001507502
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FURX | 7,160 | — |
Shares reported on the most recent Form 4, priced at the 2014-03-04 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FURX | SELL | 2013-03-11 | 2013-03-14 | $41.25 | $330K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.